Methods and products for nucleic acid production and delivery

Patent metadata

Field	Value
Publication number	US-9770489-B2
Application number	US-201514761461-A
Country	US
Kind code	B2
Filing date	Jan 30, 2015
Priority date	Jan 31, 2014
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.

First claim

What is claimed is:

1. An in vivo method for treating dystrophic epidermolysis bullosa, comprising
delivering a synthetic RNA encoding a gene-editing protein that targets a COL7 gene to a patient in need thereof and
delivering a COL7 repair template to the patient,
thereby editing the COL7 gene, wherein:
the synthetic RNA and repair template are delivered to the patient's keratinocytes by injection to the epidermis and
the gene-editing protein comprises a DNA-binding domain and a nuclease domain and causes a double-strand break in the COL7 gene of the patient's keratinocytes.

2. The method of claim 1 , wherein the gene-editing protein corrects or eliminates, either alone or in combination with one or more other molecules or gene-editing proteins, a mutation that is at least partially responsible for a disease phenotype.

3. The method of claim 1 , wherein the COL7 repair template is a single-stranded DNA molecule or a double-stranded DNA molecule.

4. The method of claim 1 , wherein the COL7 repair template does not contain a binding site of the gene-editing protein.

5. The method of claim 1 , wherein the gene-editing protein targets a nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 78.

6. The method of claim 1 , wherein the gene-editing protein is selected from the group consisting of a nuclease, a transcription activator-like effector nuclease (TALEN), a zinc-finger nuclease, a meganuclease, a nickase, and a clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein.

7. The method of claim 1 , wherein the synthetic RNA molecule further comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61P7/06

  Antianaemics · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title